NeoGenomics, Inc. (NEO) Stock Analysis
Healthcare · Diagnostics & Research · NasdaqCM
NeoGenomics, Inc. (NEO) posted $727.33M in revenue for fiscal 2025 (up 10.1% year over year), with a net loss of $108.03M, and has compounded revenue about 10.4%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on NeoGenomics, Inc.
NeoGenomics, Inc. has grown revenue from $231.81M to $727.33M over the last 10 fiscal years, compounding about 10.4% a year. The most recent year was up 10.1%, roughly in line with its longer-run pace.
Net margin sits at -14.9%, down 3 points year over year on a 43.2% gross margin. It carries about $341.86M of total debt.
The one thing worth a second look in the filings is heavy debt load.
Synthesised from NeoGenomics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
NeoGenomics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $231.81M | $240.25M | $276.74M | $408.83M | $444.45M | $484.33M | $509.73M | $591.64M | $660.57M | $727.33M |
| Gross profit | $98.10M | $101.96M | $127.27M | $196.84M | $185.89M | $187.06M | $187.90M | $244.60M | $290.10M | $314.29M |
| Net income | $-6.14M | $-396,000 | $2.64M | $8.01M | $4.17M | $-8.35M | $-144.25M | $-87.97M | $-78.73M | $-108.03M |
| Net margin | -2.6% | -0.2% | 1.0% | 2.0% | 0.9% | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
Source: NeoGenomics, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
NeoGenomics, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Heavy debt loadTotal debt of $341.9M is 65.4× last year's operating cash flow — it would take years of cash flow to clear.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -14.9%).
Explore 16 years of NeoGenomics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NEO in your portfolio →
NeoGenomics, Inc. financial history by metric
Compare NeoGenomics, Inc. with peers
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics, Inc. — frequently asked questions
What is NeoGenomics, Inc.'s revenue?
NeoGenomics, Inc. (NEO) reported revenue of $727.33M for fiscal year 2025, up 10.1% from the prior year, according to its SEC filings.
Is NeoGenomics, Inc. profitable?
No — NEO reported a net loss of $-108.03M in fiscal 2025.
What is NEO's P/E ratio?
NeoGenomics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is NeoGenomics, Inc. growing?
NEO's revenue grew at roughly 10.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does NeoGenomics, Inc. have?
As of fiscal year 2025, NEO carried roughly $341.86M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is NeoGenomics, Inc.'s gross margin?
NEO's gross margin was 43.2% in fiscal 2025 — gross profit of $314.29M on revenue of $727.33M.
What is NeoGenomics, Inc.'s market cap?
NeoGenomics, Inc. (NEO) has a market capitalization of about $1.47B, based on the latest data in our nightly-refreshed cache.
When does NeoGenomics, Inc.'s fiscal year end?
NEO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from NeoGenomics, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.